BC Extra | Sep 13, 2019
Clinical News

Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal   Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for...
BC Extra | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

On Phase III AML meet, Celgene to submit regulatory applications 1H20  Celgene Corp. (NASDAQ:CELG) plans to submit regulatory applications for CC-486 next half after the cytosine nucleoside analog met the primary and secondary endpoints in...
BC Innovations | Jan 30, 2019
Distillery Techniques


TECHNOLOGY: Plasma markers Serum levels of NEFL could help predict disease progression in familial AD. In a longitudinal study of 196 patients with familial AD, the rate at which NEFL serum levels increased annually was...
BC Extra | Jan 23, 2019
Preclinical News

Neurofilament light chain could predict familial Alzheimer's progression

Researchers showed that measuring neurofilament light (NEFL; NF-L) chain could predict progression in familial Alzheimer's disease, suggesting the protein could be used as a biomarker and for developing diagnostics for the disease. In a paper...
BC Week In Review | Nov 30, 2018
Clinical News

Disarm validates biomarkers for SARM1 inhibition

Disarm Therapeutics Inc. (Cambridge, Mass.), which is developing small molecule inhibitors of sterile α and TIR motif containing 1 (SARM1) to prevent axonal degeneration in a range of neurological disorders, said it validated two biomarkers...
Items per page:
1 - 5 of 5